Libtayo May Treat Advanced Skin Cancer in RDEB Patients, Case Report Shows
News
The immunotherapy Libtayo (cemiplimab-rwlc) may be a promising treatment for the skin cancers that sometimes appear in people with recessive dystrophic epidermolysis bullosa (RDEB) as a result of chronic ... Read more